Burning Rock Biotech Stock (NASDAQ:BNR), Analyst Ratings, Price Targets, Predictions

The latest price target for Burning Rock Biotech (NASDAQ: BNR) was reported by CICC on July 14, 2021. The analyst firm set a price target for $39.94 expecting BNR to rise to within 12 months (a possible 5133.23% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Burning Rock Biotech (NASDAQ: BNR) was provided by CICC, and Burning Rock Biotech initiated their outperform rating.

There is no last upgrade for Burning Rock Biotech.

There is no last downgrade for Burning Rock Biotech.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Burning Rock Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Burning Rock Biotech was filed on July 14, 2021 so you should expect the next rating to be made available sometime around July 14, 2022.

While ratings are subjective and will change, the latest Burning Rock Biotech (BNR) rating was a initiated with a price target of $0.00 to $39.94. The current price Burning Rock Biotech (BNR) is trading at is $0.76, which is within the analyst’s predicted range.